J B Chemicals & Pharmaceuticals Ltd
J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]
- Market Cap ₹ 16,407 Cr.
- Current Price ₹ 2,119
- High / Low ₹ 2,224 / 1,339
- Stock P/E 40.0
- Book Value ₹ 321
- Dividend Yield 0.84 %
- ROCE 22.6 %
- ROE 17.8 %
- Face Value ₹ 2.00
Pros
- Company is expected to give good quarter
- Company has been maintaining a healthy dividend payout of 31.7%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
802 | 866 | 1,022 | 1,144 | 1,210 | 1,344 | 1,408 | 1,643 | 1,775 | 2,043 | 2,424 | 3,149 | |
701 | 760 | 874 | 964 | 1,004 | 1,112 | 1,191 | 1,337 | 1,397 | 1,482 | 1,881 | 2,454 | |
Operating Profit | 101 | 106 | 148 | 180 | 206 | 232 | 218 | 306 | 378 | 560 | 543 | 696 |
OPM % | 13% | 12% | 14% | 16% | 17% | 17% | 15% | 19% | 21% | 27% | 22% | 22% |
789 | 27 | -27 | 11 | 58 | 50 | 37 | 41 | 41 | 112 | 39 | 10 | |
Interest | 24 | 4 | 6 | 7 | 11 | 5 | 3 | 5 | 3 | 7 | 5 | 36 |
Depreciation | 22 | 25 | 28 | 39 | 41 | 47 | 57 | 56 | 66 | 69 | 73 | 114 |
Profit before tax | 843 | 104 | 87 | 146 | 212 | 230 | 194 | 287 | 349 | 597 | 505 | 555 |
Tax % | 20% | 23% | 30% | 31% | 23% | 20% | 28% | 32% | 22% | 25% | 24% | 26% |
Net Profit | 678 | 79 | 62 | 100 | 163 | 184 | 139 | 194 | 272 | 449 | 386 | 410 |
EPS in Rs | 80.03 | 9.38 | 7.26 | 11.84 | 19.16 | 21.70 | 16.55 | 24.11 | 35.20 | 57.96 | 49.86 | 52.96 |
Dividend Payout % | 51% | 32% | 41% | 118% | 26% | 5% | 12% | 21% | 31% | 28% | 33% | 34% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 17% |
3 Years: | 21% |
TTM: | 30% |
Compounded Profit Growth | |
---|---|
10 Years: | 21% |
5 Years: | 31% |
3 Years: | 16% |
TTM: | 15% |
Stock Price CAGR | |
---|---|
10 Years: | 39% |
5 Years: | 52% |
3 Years: | 44% |
1 Year: | 34% |
Return on Equity | |
---|---|
10 Years: | 15% |
5 Years: | 18% |
3 Years: | 20% |
Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
17 | 17 | 17 | 17 | 17 | 17 | 17 | 16 | 15 | 15 | 15 | 15 | |
Reserves | 953 | 1,003 | 1,026 | 978 | 1,167 | 1,347 | 1,425 | 1,464 | 1,420 | 1,794 | 2,119 | 2,465 |
71 | 50 | 93 | 127 | 193 | 49 | 29 | 26 | 29 | 45 | 55 | 557 | |
157 | 230 | 215 | 365 | 270 | 262 | 294 | 286 | 349 | 376 | 412 | 516 | |
Total Liabilities | 1,198 | 1,300 | 1,351 | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,554 |
276 | 334 | 311 | 329 | 440 | 679 | 640 | 621 | 651 | 634 | 1,277 | 1,912 | |
CWIP | 39 | 5 | 46 | 55 | 135 | 4 | 17 | 15 | 16 | 26 | 19 | 44 |
Investments | 302 | 398 | 500 | 552 | 479 | 411 | 434 | 457 | 403 | 678 | 13 | 206 |
581 | 563 | 494 | 552 | 594 | 580 | 674 | 699 | 743 | 894 | 1,293 | 1,392 | |
Total Assets | 1,198 | 1,300 | 1,351 | 1,487 | 1,648 | 1,674 | 1,765 | 1,792 | 1,814 | 2,231 | 2,601 | 3,554 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
880 | 84 | -14 | 127 | 140 | 201 | 123 | 194 | 276 | 315 | 170 | 626 | |
-261 | -116 | -142 | -112 | -26 | -45 | -21 | -28 | 24 | -231 | 2 | -962 | |
-526 | -31 | 12 | -1 | -100 | -184 | -60 | -156 | -306 | -87 | -138 | 357 | |
Net Cash Flow | 93 | -63 | -144 | 13 | 15 | -28 | 43 | 11 | -6 | -3 | 34 | 20 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 62 | 81 | 84 | 84 | 82 | 72 | 78 | 68 | 71 | 70 | 84 | 67 |
Inventory Days | 117 | 104 | 120 | 122 | 146 | 138 | 145 | 149 | 159 | 181 | 178 | 135 |
Days Payable | 51 | 60 | 54 | 63 | 71 | 68 | 75 | 72 | 97 | 97 | 97 | 75 |
Cash Conversion Cycle | 128 | 124 | 150 | 143 | 158 | 142 | 148 | 146 | 133 | 153 | 164 | 127 |
Working Capital Days | 98 | 80 | 99 | 56 | 96 | 88 | 101 | 97 | 87 | 99 | 130 | 124 |
ROCE % | 11% | 8% | 13% | 13% | 15% | 14% | 11% | 18% | 23% | 33% | 23% | 23% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
31 May - Allotment of Equity Shares on exercise of Stock options pursuant to Employee Stock Option Scheme
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
30 May - Disclosure under regulation 30 of the SEBI (LODR) Regulations, 2015 - Transcript of Investors/Analysts call
- Intimation Of Schedule Of Analysts/Institutional Investors Meet 26 May
- Intimation Of Record Date Pursuant To Regulation 42 Of The Securities & Exchange Board Of India (LODR) Regulations, 2015 26 May
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 25 May
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Mar 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Sep 2019TranscriptNotesPPT
Revenue Split Q1 FY23
Domestic Formulations - 53%
Export Formulations - 31%
Contract Manufacturing - 13%
APIs - 3% [1]